Recurrent Middle Eastern Differentiated Thyroid Carcinoma Has Worse Outcomes Than Persistent Disease
Open Access
- 25 March 2024
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (7) , 1877
Abstract
Background: Despite the excellent prognosis of differentiated thyroid carcinoma (DTC), recurrent and persistent disease remain major challenges. Emerging studies to differentiate between recurrent and persistent disease are controversial, with studies from the Middle East lacking. Methods: We retrospectively analyzed 1691 patients who underwent surgery ± I131 treatment for DTC, with a median age of 38.7 years and median follow-up of 95.3 months. Results: We found a similar prevalence rate for persistent and recurrent disease (17.7% vs. 17.9%) in Middle Eastern DTC patients. Relative to patients with persistent disease, patients with recurrent disease were significantly older (median age: 36.1 vs. 45.8 years; p < 0.0001) and were more likely to have ATA high-risk tumors (61.5% vs. 75.2%; p = 0.0003). On multivariate logistic regression analysis, both T and N status were independent predictors for recurrent as well as structural persistent disease. However, older age, bilaterality and extrathyroidal extension were independent predictors of recurrent disease alone. In addition, patients with recurrent disease had significantly worse cancer-specific survival (p < 0.0001), which remained significant in multivariate analysis. Conclusions: Although persistent and recurrent disease in Middle Eastern DTC have similar frequencies, recurrent disease has worse outcomes compared to persistent disease. Hence, differentiating recurrence from persistence has great potential clinical relevance for therapeutic and follow-up approaches, contributing to improving the outcomes of DTC patients of Middle Eastern ethnicity.Keywords
This publication has 31 references indexed in Scilit:
- Patient Report of Recurrent and Persistent Thyroid CancerThyroid®, 2020
- Time-Varying Pattern of Mortality and Recurrence from Papillary Thyroid Cancer: Lessons from a Long-Term Follow-UpThyroid®, 2019
- Back so soon? Is early recurrence of papillary thyroid cancer really just persistent disease?Surgery, 2018
- Predictors for papillary thyroid cancer persistence and recurrence: a retrospective analysis with a 10‐year follow‐up cohort studyClinical Endocrinology, 2016
- 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerThyroid®, 2016
- Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasisJournal of Surgical Oncology, 2015
- Variations in clinicopathologic characteristics of thyroid cancer among racial ethnic groups: analysis of a large public city hospital and the SEER databaseThe American Journal of Surgery, 2013
- Prognostic Factors for Recurrence of Papillary Thyroid Carcinoma in the Lymph Nodes, Lung, and Bone: Analysis of 5,768 Patients with Average 10‐year Follow‐upWorld Journal of Surgery, 2012
- Early Recurrence of Papillary and Follicular Thyroid Carcinoma Predicts a Worse OutcomeThyroid®, 2009
- Clinical Course of Thyroid Carcinoma After Neck DissectionThe Laryngoscope, 2003